Endocrine Disorders Induced by PD-1/PD-L1 Inhibitor and Related Treatment

Immune checkpoint therapy is a new mode of tumor therapy. At present, many kinds of PD-1/PD-L1 inhibitors have been approved for clinical application on various tumors, such as malignant melanoma, lung cancer, bladder cancer, lymphoma, etc. However, with the gradual promotion and application in clin...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	LAI Yanliang, GENG Yan, YANG Bingquan
Formato:	article
Lenguaje:	ZH
Publicado:	Magazine House of Cancer Research on Prevention and Treatment 2021
Materias:	immune checkpoint pd-1 immune-related adverse events endocrine disorders Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/d8ae6841853849339273588500c2bc99
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d8ae6841853849339273588500c2bc99
record_format	dspace
spelling	oai:doaj.org-article:d8ae6841853849339273588500c2bc992021-12-03T09:25:17ZEndocrine Disorders Induced by PD-1/PD-L1 Inhibitor and Related Treatment1000-857810.3971/j.issn.1000-8578.2021.21.0365https://doaj.org/article/d8ae6841853849339273588500c2bc992021-11-01T00:00:00Zhttp://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2021.21.0365https://doaj.org/toc/1000-8578Immune checkpoint therapy is a new mode of tumor therapy. At present, many kinds of PD-1/PD-L1 inhibitors have been approved for clinical application on various tumors, such as malignant melanoma, lung cancer, bladder cancer, lymphoma, etc. However, with the gradual promotion and application in clinical practice, various immune-related adverse reactions caused by PD-1/PD-L1 inhibitors have attracted extensive attention. Especially in recent years, a number of adverse reactions related to endocrine gland injury have been reported. This paper reviews the research status and corresponding clinical treatment methods of endocrine gland related adverse reactions caused by PD-1/PD-L1 inhibitors.LAI YanliangGENG YanYANG BingquanMagazine House of Cancer Research on Prevention and Treatmentarticleimmune checkpointpd-1immune-related adverse eventsendocrine disordersNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ZHZhongliu Fangzhi Yanjiu, Vol 48, Iss 11, Pp 1035-1040 (2021)
institution	DOAJ
collection	DOAJ
language	ZH
topic	immune checkpoint pd-1 immune-related adverse events endocrine disorders Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	immune checkpoint pd-1 immune-related adverse events endocrine disorders Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 LAI Yanliang GENG Yan YANG Bingquan Endocrine Disorders Induced by PD-1/PD-L1 Inhibitor and Related Treatment
description	Immune checkpoint therapy is a new mode of tumor therapy. At present, many kinds of PD-1/PD-L1 inhibitors have been approved for clinical application on various tumors, such as malignant melanoma, lung cancer, bladder cancer, lymphoma, etc. However, with the gradual promotion and application in clinical practice, various immune-related adverse reactions caused by PD-1/PD-L1 inhibitors have attracted extensive attention. Especially in recent years, a number of adverse reactions related to endocrine gland injury have been reported. This paper reviews the research status and corresponding clinical treatment methods of endocrine gland related adverse reactions caused by PD-1/PD-L1 inhibitors.
format	article
author	LAI Yanliang GENG Yan YANG Bingquan
author_facet	LAI Yanliang GENG Yan YANG Bingquan
author_sort	LAI Yanliang
title	Endocrine Disorders Induced by PD-1/PD-L1 Inhibitor and Related Treatment
title_short	Endocrine Disorders Induced by PD-1/PD-L1 Inhibitor and Related Treatment
title_full	Endocrine Disorders Induced by PD-1/PD-L1 Inhibitor and Related Treatment
title_fullStr	Endocrine Disorders Induced by PD-1/PD-L1 Inhibitor and Related Treatment
title_full_unstemmed	Endocrine Disorders Induced by PD-1/PD-L1 Inhibitor and Related Treatment
title_sort	endocrine disorders induced by pd-1/pd-l1 inhibitor and related treatment
publisher	Magazine House of Cancer Research on Prevention and Treatment
publishDate	2021
url	https://doaj.org/article/d8ae6841853849339273588500c2bc99
work_keys_str_mv	AT laiyanliang endocrinedisordersinducedbypd1pdl1inhibitorandrelatedtreatment AT gengyan endocrinedisordersinducedbypd1pdl1inhibitorandrelatedtreatment AT yangbingquan endocrinedisordersinducedbypd1pdl1inhibitorandrelatedtreatment
_version_	1718373361203019776

Endocrine Disorders Induced by PD-1/PD-L1 Inhibitor and Related Treatment

Ejemplares similares